TY - JOUR
T1 - Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving Lovastatin
AU - Norman, Douglas J.
AU - Illingworth, D. Roger
AU - Munson, Jennifer
AU - Hosenpud, Jeffrey
PY - 1988/1/7
Y1 - 1988/1/7
N2 - To the Editor: Lovastatin, a new cholesterol-lowering drug that inhibits 3-hydroxy-3-methylglutaryl-CoA reductase,1 can cause myositis and elevations in serum creatine kinase levels by means of an unknown mechanism2 in a small number (<0.5 percent) of patients. Severe muscle damage and acute renal failure due to lovastatin have not been reported. Our patient, a 53-year-old man with heterozygous familial hypercholesterolemia, received a cardiac allograft in July 1986. Because of refractory hypercholesterolemia (total plasma cholesterol, 468 ml per deciliter [12.6 mmol per liter]; triglycerides, 236 mg per deciliter [2.67 mmol per liter]), he was started on lovastatin (20 mg twice daily) in.
AB - To the Editor: Lovastatin, a new cholesterol-lowering drug that inhibits 3-hydroxy-3-methylglutaryl-CoA reductase,1 can cause myositis and elevations in serum creatine kinase levels by means of an unknown mechanism2 in a small number (<0.5 percent) of patients. Severe muscle damage and acute renal failure due to lovastatin have not been reported. Our patient, a 53-year-old man with heterozygous familial hypercholesterolemia, received a cardiac allograft in July 1986. Because of refractory hypercholesterolemia (total plasma cholesterol, 468 ml per deciliter [12.6 mmol per liter]; triglycerides, 236 mg per deciliter [2.67 mmol per liter]), he was started on lovastatin (20 mg twice daily) in.
UR - http://www.scopus.com/inward/record.url?scp=0023839115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023839115&partnerID=8YFLogxK
U2 - 10.1056/NEJM198801073180110
DO - 10.1056/NEJM198801073180110
M3 - Letter
C2 - 3275891
AN - SCOPUS:0023839115
SN - 0028-4793
VL - 318
SP - 46
EP - 47
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 1
ER -